Search

Your search keyword '"Comes, Alessia"' showing total 19 results
Start Over Author "Comes, Alessia"
19 results on '"Comes, Alessia"'

2. Association of BMI and Change in Weight With Mortality in Patients With Fibrotic Interstitial Lung Disease

Author

Comes, Alessia, Wong, Alyson W., Fisher, Jolene H., Morisset, Julie, Johannson, Kerri A., Farrand, Erica, Fell, Charlene D., Kolb, Martin, Manganas, Hélène, Cox, Gerard, Gershon, Andrea S., Halayko, Andrew J., Hambly, Nathan, Khalil, Nasreen, Sadatsafavi, Mohsen, Shapera, Shane, To, Teresa, Wilcox, Pearce G., Collard, Harold R., and Ryerson, Christopher J.

Published
2022
Full Text
View/download PDF

5. A randomized trial of pamrevlumab in patients with COVID‐19 pneumonia

Author

Sgalla, Giacomo, primary, Leone, Paolo Maria, additional, Gualano, Gina, additional, Simonetti, Jacopo, additional, Comes, Alessia, additional, Verdirosi, Diana, additional, Di Gennaro, Francesco, additional, Larici, Anna Rita, additional, Ianniello, Stefania, additional, Cicchetti, Giuseppe, additional, Fusco, Nicoletta, additional, Pani, Marcello, additional, Palmieri, Fabrizio, additional, and Richeldi, Luca, additional

Published
2023
Full Text
View/download PDF

7. Response

Author

Comes, Alessia, primary and Ryerson, Christopher J., additional

Published
2022
Full Text
View/download PDF

9. Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry

Author

Hambly, Nathan, primary, Farooqi, M. Malik, additional, Dvorkin-Gheva, Anna, additional, Donohoe, Kathryn, additional, Garlick, Kristopher, additional, Scallan, Ciaran, additional, Chong, Sy Giin, additional, MacIsaac, Sarah, additional, Assayag, Deborah, additional, Johannson, Kerri A., additional, Fell, Charlene D., additional, Marcoux, Veronica, additional, Manganas, Helene, additional, Morisset, Julie, additional, Comes, Alessia, additional, Fisher, Jolene H., additional, Shapera, Shane, additional, Gershon, Andrea S., additional, To, Teresa, additional, Wong, Alyson W., additional, Sadatsafavi, Mohsen, additional, Wilcox, Pierce G., additional, Halayko, Andrew J., additional, Khalil, Nasreen, additional, Cox, Gerard, additional, Richeldi, Luca, additional, Ryerson, Christopher J., additional, and Kolb, Martin, additional

Published
2022
Full Text
View/download PDF

11. Prescribing Patterns and Tolerability of Mycophenolate and Azathioprine in Patients with Non-IPF Fibrotic Interstitial Lung Disease

Author

Wong, Alyson W., primary, Khor, Yet H, additional, Donohoe, Kathryn, additional, Comes, Alessia, additional, Marcoux, Veronica, additional, Fisher, Jolene H, additional, Johannson, Kerri A, additional, Assayag, Deborah, additional, Morisset, Julie, additional, Shapera, Shane, additional, Khalil, Nasreen, additional, Fell, Charlene D, additional, Manganas, Helene, additional, Cox, Gerard, additional, To, Teresa, additional, Gershon, Andrea S, additional, Hambly, Nathan, additional, Halayko, Andrew J, additional, Sadatsafavi, Mohsen, additional, Wilcox, Pearce G, additional, Kolb, Martin, additional, Richeldi, Luca, additional, and Ryerson, Christopher J, additional

Published
2021
Full Text
View/download PDF

14. Prescribing Patterns and Tolerability of Mycophenolate and Azathioprine in Patients with Nonidiopathic Pulmonary Fibrosis Fibrotic Interstitial Lung Disease.

Author

Wong, Alyson W., Khor, Yet H., Donohoe, Kathryn, Comes, Alessia, Marcoux, Veronica, Fisher, Jolene H., Johannson, Kerri A., Assayag, Deborah, Morisset, Julie, Shapera, Shane, Khalil, Nasreen, Fell, Charlene D., Manganas, Helene, Cox, Gerard, To, Teresa, Gershon, Andrea S., Hambly, Nathan, Halayko, Andrew J., Sadatsafavi, Mohsen, and Wilcox, Pearce G.

Subjects
IDIOPATHIC pulmonary fibrosis, AZATHIOPRINE, INTERSTITIAL lung diseases, FIBROSIS, IMMUNOSUPPRESSIVE agents
Published
2022
Full Text
View/download PDF

16. Advances with pharmacotherapy for the treatment of interstitial lung disease

Author

Comes, Alessia, Sgalla, Giacomo, Perrotta, Alessandro, and Richeldi, Luca

Abstract

ABSTRACTIntroductionIn recent decades, the primary focus of pharmaceutical research in interstitial lung diseases (ILD) has been on idiopathic pulmonary fibrosis (IPF). Recently, pharmaceutical development has also focused on other forms of ILDs, including connective tissue diseases associated ILD, fibrotic hypersensitivity pneumonitis, and sarcoidosis.Areas CoveredThe authors summarize the advances in pharmacotherapy for the treatment of ILD. Specifically, the authors review the most recent studies and discuss the most recent research findings and future prospects.Expert opinionData collected over the past years have confirmed the efficacy of antifibrotic drugs on slowing disease progression in IPF. The usual strategy for CTD-ILD management is represented by the combined use of corticosteroids and immunosuppressive agents. There is an urgent need for new target therapies. The concept of progressive fibrosing ILD has emerged in the ILD community in recent years, which has led to grouping several diseases with a common disease behavior to find an effective treatment . At present, selecting the best therapy in ILDs should be reasonably performed on a case-by-case basis through a multidisciplinary team discussion in tertiary ILD centers, taking into consideration patients’ symptoms, lung functional trends, and radiological changes.

Published
2022
Full Text
View/download PDF

17. Impact of chest imaging quality on the diagnosis of the usual interstitial pneumonia pattern: a hub and spoke study

Author

Sgalla, Giacomo, primary, Larici, Anna Rita, additional, Re, Antonina, additional, Farchione, Alessandra, additional, Cicchetti, Giuseppe, additional, Calandriello, Lucio, additional, Comes, Alessia, additional, Golfi, Nicoletta, additional, Iovene, Bruno, additional, Varone, Francesco, additional, Manfredi, Riccardo, additional, and Richeldi, Luca, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results